These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 9488584

  • 1. Identifying markers for pancreatic cancer by gene expression analysis.
    Zhou W, Sokoll LJ, Bruzek DJ, Zhang L, Velculescu VE, Goldin SB, Hruban RH, Kern SE, Hamilton SR, Chan DW, Vogelstein B, Kinzler KW.
    Cancer Epidemiol Biomarkers Prev; 1998 Feb; 7(2):109-12. PubMed ID: 9488584
    [Abstract] [Full Text] [Related]

  • 2. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, Bamberger AM, Greenson J, Brand RE, Ramachandran V, Logsdon CD.
    Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
    [Abstract] [Full Text] [Related]

  • 3. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [Abstract] [Full Text] [Related]

  • 4. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
    Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, Kedra B, Jurkowska G, Szmitkowski M.
    Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
    [Abstract] [Full Text] [Related]

  • 5. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT, Tao HQ, Zou SC.
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [Abstract] [Full Text] [Related]

  • 6. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
    Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M.
    Clin Cancer Res; 2006 Jan 15; 12(2):442-6. PubMed ID: 16428484
    [Abstract] [Full Text] [Related]

  • 7. [Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas].
    Yamaguchi K, Nagano M, Torada N, Hamasaki N, Kawakita M, Tanaka M.
    Rinsho Byori; 2004 Apr 15; 52(4):336-9. PubMed ID: 15164602
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ.
    Chin J Dig Dis; 2006 Apr 15; 7(3):170-4. PubMed ID: 16808798
    [Abstract] [Full Text] [Related]

  • 9. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma.
    Yukawa N, Yoshikawa T, Akaike M, Sugimasa Y, Takemiya S, Yanoma S, Noguchi Y, Takanashi Y.
    Br J Surg; 2001 Dec 15; 88(12):1596-601. PubMed ID: 11736971
    [Abstract] [Full Text] [Related]

  • 10. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
    Yoneda K, Iida H, Endo H, Hosono K, Akiyama T, Takahashi H, Inamori M, Abe Y, Yoneda M, Fujita K, Kato S, Nozaki Y, Ichikawa Y, Uozaki H, Fukayama M, Shimamura T, Kodama T, Aburatani H, Miyazawa C, Ishii K, Hosomi N, Sagara M, Takahashi M, Ike H, Saito H, Kusakabe A, Nakajima A.
    Int J Oncol; 2009 Jul 15; 35(1):33-40. PubMed ID: 19513549
    [Abstract] [Full Text] [Related]

  • 11. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
    Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, Conrad T, Witzigmann H, Weimann A, Schütte C, Hauss J, Büchler M, Thiery J.
    Clin Cancer Res; 2009 Jun 01; 15(11):3812-9. PubMed ID: 19470732
    [Abstract] [Full Text] [Related]

  • 12. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y, Okusaka T, Ueno H, Ikeda M, Morizane C, Najima M.
    Gan To Kagaku Ryoho; 2004 Sep 01; 31(9):1443-6. PubMed ID: 15446574
    [Abstract] [Full Text] [Related]

  • 13. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
    Cerwenka H, Aigner R, Bacher H, Werkgartner G, el-Shabrawi A, Quehenberger F, Mischinger HJ.
    Anticancer Res; 1999 Sep 01; 19(1B):849-51. PubMed ID: 10216504
    [Abstract] [Full Text] [Related]

  • 14. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
    Yang YC, Zhao YP, Liao Q, Zhang TP, Hu Y, Dai MH.
    Zhonghua Wai Ke Za Zhi; 2009 Jul 01; 47(13):999-1001. PubMed ID: 19957811
    [Abstract] [Full Text] [Related]

  • 15. [Early detection of pancreatic cancer by serum markers].
    Nakae Y, Naruse S, Shibata T, Kitagawa M, Kondo T, Hayakawa T, Kuno N, Kurimoto K.
    Rinsho Byori; 1994 Feb 01; 42(2):139-42. PubMed ID: 7511183
    [Abstract] [Full Text] [Related]

  • 16. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q, Zhao YP, Yang YC, Li LJ, Long X, Han SM.
    Hepatobiliary Pancreat Dis Int; 2007 Dec 01; 6(6):641-5. PubMed ID: 18086633
    [Abstract] [Full Text] [Related]

  • 17. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
    Kokhanenko NIu, Ignashov AM, Varga EV, Polkanova MS, Aleshina LA, Kimbarovskaia AA, Osipenko SK, Lebedev EG.
    Vopr Onkol; 2001 Dec 01; 47(3):294-7. PubMed ID: 11544826
    [Abstract] [Full Text] [Related]

  • 18. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H, Kaya M, Cengiz A.
    Hepatogastroenterology; 2003 Dec 01; 50(53):1669-74. PubMed ID: 14571813
    [Abstract] [Full Text] [Related]

  • 19. CA19-9: the Italian experience.
    Gullo L.
    Pancreas; 1994 Nov 01; 9(6):717-9. PubMed ID: 7846014
    [Abstract] [Full Text] [Related]

  • 20. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.
    Holten-Andersen MN, Nielsen HJ, Sørensen S, Jensen V, Brünner N, Christensen IJ.
    Eur J Cancer; 2006 Aug 01; 42(12):1889-96. PubMed ID: 16809030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.